Abstracts Archive - Page 763 of 2607 - ACR Meeting Abstracts

Abstract Number: 0868 • ACR Convergence 2021
Cell-bound Complement Activation Products (CB-CAPs) Predicts Type 1 SLE Activity
Jennifer Rogers¹, Rory Bloch², Amanda Eudy¹, David Pisetsky³, Roberta Alexander², John Conklin², Kai Sun¹, Rebecca Sadun¹, Lisa Criscione-Schreiber⁴, Jayanth Doss¹ and Megan Clowse⁵, ¹Duke University, Durham, NC, ²Exagen Inc., Vista, CA, ³Duke University Medical Center, Durham, NC, ⁴Duke University School of Medicine, Durham, NC, ⁵Duke University, Chapel Hill, NC
Background/Purpose: SLE is a multisystem autoimmune disease that displays diverse manifestations that can be categorized into two broad types. Type 1 SLE activity includes inflammatory…
Abstract Number: 0869 • ACR Convergence 2021
Comparison of Two Frailty Definitions in Women with Systemic Lupus Erythematosus
Sarah Lieber¹, Musarrat Nahid², Alexandra Legge³, Mangala Rajan², Robyn Lipschultz¹, Myriam Lin¹ and Lisa Mandl¹, ¹Hospital for Special Surgery, New York, NY, ²Weill Cornell Medicine, New York, NY, ³Dalhousie University, Halifax, NS, Canada
Background/Purpose: Frailty is a novel risk factor for adverse health outcomes in systemic lupus erythematosus (SLE). Multiple definitions of frailty, including the Fried definition (FD),…
Abstract Number: 0870 • ACR Convergence 2021
Blood Brain Barrier Integrity and Brain Imaging Patterns in Patients with SLE
Shiran Aharon¹, Dafna Ben-Bashat², Orna Aizenstein³, Moran Artzi⁴, Mark Berman⁵, Victoria Furer⁶, Marina Anouk⁷, Yael Lahat⁸, Jonathan Wollman⁹, Ofir Elalouf⁹, Ari Polachek¹⁰ and Daphna Paran¹¹, ¹Wohl Institute of Advanced Imaging, Tel-Aviv Sourasky Medical Center, Sagol School of Neuroscience, Sackler Faculty of Medicine, Tel-Aviv, Israel, ²Wohl Institute of Advanced Imaging, Tel-Aviv Sourasky Medical Center, Tel-Aviv University, Tel-Aviv, Israel, ³Department of Neuroradiology Tel-Aviv Sourasky Medical Center, Tel-Aviv University, Tel-Aviv, Israel, ⁴Wohl Institute of Advanced Imaging, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel, ⁵Department of Rheumatology , Tel-Aviv Sourasky Medical Center, Tel-Aviv University, Tel Aviv, Israel, ⁶Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ⁷Department of Rheumatology, Tel-Aviv Sourasky Medical Center, Tel-Aviv University, Tel-Aviv, Israel, ⁸Department of Rheumatology , Tel-Aviv Sourasky Medical Center, Tel-Aviv University, Tel-Aviv, Israel, ⁹Tel Aviv Medical Center, Herzliya, Israel, ¹⁰Sourasky Medical Center, Petah-Tikva, Israel, ¹¹Tel Aviv Sourasky Medical Center-Ichilov Hospital, Even Yehuda, Israel
Background/Purpose: The pathogenesis of neuropsychiatric SLE (NPSLE) has not been fully elucidated. Recent evidence suggests impaired blood brain barrier (BBB) integrity as a possible mechanism…
Abstract Number: 0871 • ACR Convergence 2021
The Association of Hydroxychloroquine Dosing with Adverse Cardiovascular Events in Patients with Systemic Lupus Erythematosus
Alejandra Londono Jimenez¹, Mohammad Hashim Mustehsan¹, Ana Valle², Jammie Law³, Shudan Wang², Maria Auxiliadora Salgado Guerrero⁴, David Briceno¹ and Anna Broder¹, ¹Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, ²Albert Einstein College of Medicine/Montefiore Medical Center, New York, NY, ³Montefiore Medical Center, Bronx, NY, ⁴Jacobi Medical Center/Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Current guidelines recommend use of hydroxychloroquine (HCQ) at doses not exceeding 5mg/kg based solely on the increased risk of retinopathy at higher doses. This…
Abstract Number: 0872 • ACR Convergence 2021
Lack of Association Between Cognitive Test Performance and Cognitive Symptoms in Systemic Lupus Erythematosus (SLE)
Sudha Raghunath¹, Yifat Glikmann-Johnston¹, Emma Guymer¹, Eric Morand², Julie Stout¹ and Alberta Hoi³, ¹Monash University, Melbourne, Australia, ²School of Clinical Sciences at Monash Health, Monash University Faculty of Medicine, Nursing and Health Sciences, Monash Medical Centre Clayton, Melbourne, Australia, ³Department of Rheumatology, Monash Health & Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, Australia
Background/Purpose: Cognitive dysfunction (CD) is reported to affect approximately 40% of SLE patients (1). Mood disorders have been associated with both cognitive symptoms and cognitive…
Abstract Number: 0873 • ACR Convergence 2021
Clinical and Serological Characteristics of Latin American Patients with Lupus Enteritis: A Case-Control Study
Marcela Muñoz-Urbano¹, Julian Sanchez-Bautista², Yeison Santamaria-Alza¹, Diana C. Quintero-González³, Andres Ramirez², Adriana Lucía Vanegas-García⁴, Gloria M. Vasquez¹ and Luis Alonso Gonzalez³, ¹Rheumatology section, Universidad de Antioquia, Medellín, Colombia, ²Department of internal medicine, Universidad de Antioquia, Medellín, Colombia, ³Division of rheumatology, Universidad de Antioquia, Medellín, Colombia, ⁴Division of rheumatology, Universidad de Antioquia – Hospital San Vicente Fundación, Medellín, Colombia
Background/Purpose: Lupus enteritis (LE) is a potentially life-threatening manifestation of systemic lupus erythematosus (SLE), with an incidence ranging from 8% to 27%. Timely diagnosis is…
Abstract Number: 0874 • ACR Convergence 2021
Serum Galectin-9 and CXCL-10 but Not Their Urinary Levels Reflect Lupus Activity
Pankti Mehta, Pratibha Singh and Amita Aggarwal, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: SLE is characterized by increased type I IFN signature in the blood and immune cells. Traditionally, type I IFN signature is measured by gene…
Abstract Number: 0875 • ACR Convergence 2021
Renal Function, Adherence and Low Hydroxychloroquine Dosing Predict HCQ Blood Levels and Lupus Disease Activity
Shivani Garg¹, Karen Hansen², Betty Chewning¹ and Christie Bartels², ¹UW Madison, Madison, WI, ²University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Despite weight-based dosing, hydroxychloroquine (HCQ) efficacy varies between individuals. Our meta-analysis based on several studies found that low HCQ levels increased risk of lupus…
Abstract Number: 0876 • ACR Convergence 2021
Antibody Response in Patients with Systemic Lupus Erythematosus After a Two-dose Regimen with SARS-CoV-2 Vaccines (Preliminary Results)
Emilie Stavnsbjerg Larsen¹, Anna Christine Nilsson², Ulrik Stenz Justesen¹, Anne Voss³ and Isik Somuncu Johansen⁴, ¹Odense University Hospital, Odense C, Denmark, ²Odense Universitets Hospital, Odense C, Denmark, ³Department of Rheumatology, Odense University Hospital, Odense C, Denmark, ⁴Odense University Hospital, Odense, Denmark
Background/Purpose: Patients with Systemic Lupus Erythematosus (SLE) often receive immunosuppressive treatment for many years, resulting in higher risk of infections, including COVID-19, and infections may…
Abstract Number: 0877 • ACR Convergence 2021
Association of HCQ Blood Levels with Type 1 and 2 SLE Activity
Kai Sun¹, Amanda Eudy², Jennifer Rogers¹, Lisa Criscione-Schreiber¹, Rebecca Sadun², Jayanth Doss², Kelley Brady³, Roberta Alexander³, John Conklin³, Rory Bloch³ and Megan Clowse⁴, ¹Duke University School of Medicine, Durham, NC, ²Duke University, Durham, NC, ³Exagen Inc., Vista, CA, ⁴Duke University, Chapel Hill, NC
Background/Purpose: HCQ levels reflect adherence and have been shown to correlate with SLE outcomes. However, HCQ levels have not been studied in the context of…
Abstract Number: 0878 • ACR Convergence 2021
Investigating the Neutrophil to Lymphocyte Ratio as a Marker of SLE Disease Activity, Health-Related Quality of Life and Depression
Eleni Papachristodoulou¹, Loukas Kakoullis¹, Savvas Psarelis², Victor Hajiroussos³, Costas Christophi⁴ and Konstantinos Parperis¹, ¹University of Cyprus Medical School, Nicosia, Cyprus, ²Nicosia General Hospital/University of Cyprus Medical Schooll, Nicosia, Cyprus, ³Ygia Polyclinic Hospital, Limassol, Cyprus, ⁴Cyprus University of Technology, Limassol, Cyprus
Background/Purpose: The need for readily available markers of SLE activity has led to the evaluation of laboratory parameters, such as the neutrophil to lymphocyte ratio…
Abstract Number: 0879 • ACR Convergence 2021
Anti-dsDNA Antibodies Increase Systemic Lupus Erythematosus Cardiovascular Risk Impairing the Immune and Cardiovascular Systems
Carlos Pérez-Sánchez¹, Alejandra Patiño-Trives², Maria Angeles Aguirre³, Laura Perez-Sanchez³, Chary Lopez-Pedrera³, Maria Luque-Tevar², Maria del Carmen Ábalos-Aguilera³, Iván Arias de la Rosa⁴, Cristobal Román-Rodriguez³, Pedro Segui³, Mario Espinosa³, Pilar Font³, Nuria Barbarroja⁴, alejandro Escudero³, Eduardo Collantes-Estevez³, Jose Antonio Gonzalez-Reyes⁵, Jose Manuel Villalba⁵ and Chary lopez-pedrera³, ¹IMIBIC, Córdoba, Spain, ²Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain, ³IMIBIC/Reina Sofia Hospital/University of Córdoba, Córdoba, Spain, ⁴University of Cordoba/IMIBIC/Reina Sofia Hospital, Cordoba, Spain, ⁵Department of Cell Biology, Physiology and Immunology, University of Córdoba, Campus de Excelencia Internacional Agroalimentario, ceiA3, Cordoba, Spain
Background/Purpose: This study aimed to delineate the role of anti-dsDNA antibodies on the alterations observed in the gene profile and the activity of immune and…
Abstract Number: 0880 • ACR Convergence 2021
Health Information Use by SLE Patients Pre and During COVID-19
Francesca Cardwell¹, Susan Elliott², May Choi³, Ricky Chin³, Yvan St.Pierre⁴, Leigha Rowbottom⁵, Murray Urowitz⁶, Guillermo Ruiz-Irastorza⁷, Sasha Bernatsky⁸, Michelle Petri⁹, Susan Manzi¹⁰, Christine Peschken¹¹, Rosalind Ramsey-Goldman¹², Paul R Fortin¹³, Jungmin Shin¹⁴, Sang-Cheol Bae¹⁵, Jiacai Cho¹⁶, Anselm Mak¹⁷, John Hanly¹⁸, Anca Askanase¹⁹, Juanita Romero-Diaz²⁰, Romina Nieto²¹, Bernardo A. Pons-Estel²², Ian N. Bruce²³, Daniel Wallace²⁴ and Ann Clarke⁵, ¹University of Waterloo, Burlington, ON, Canada, ²University of Waterloo, Waterloo, ON, Canada, ³Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, ⁴Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ⁵University of Calgary, Calgary, AB, Canada, ⁶Center for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, University of Toronto, Lupus Clinic, Toronto, ON, Canada, ⁷Hospital Universitario Cruces, University of the Basque Country, Bizkaia, Spain, ⁸McGill University, Montréal, QC, Canada, ⁹Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁰Allegheny Health Network, Wexford, PA, ¹¹University of Manitoba, Winnipeg, MB, Canada, ¹²Northwestern University, Chicago, IL, ¹³CHU de Quebec - Universite Laval, Québec City, QC, Canada, ¹⁴Hanyang University Hospital, Seoul, Republic of Korea, ¹⁵Hanyang University Medical Center, Seoul, Republic of Korea, ¹⁶National University Health System (NUHS), Singapore, Singapore, ¹⁷National University of Singapore, Singapore, Singapore, ¹⁸Dalhousie University, Halifax, NS, Canada, ¹⁹Columbia University Medical Center, New York, NY, ²⁰Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Ciudad de México, Federal District, Mexico, ²¹Hospital Provincial de Rosario, Rosario, Argentina, ²²Grupo Oroo - Centro Regional de Enfermedades Autoinmunes y Reumticas (GO-CREAR), Rosario, Argentina, ²³University of Manchester, Manchester, United Kingdom, ²⁴Cedars-Sinai, Los Angeles, CA
Background/Purpose: The spread of COVID-19 misinformation is especially serious for individuals with complex diseases like SLE; conflicting and/or unfounded information can complicate a patient’s health…
Abstract Number: 0881 • ACR Convergence 2021
Economic Evaluation of Neuropsychiatric (NP) Lupus in an International Inception Cohort Using a Multistate Model Approach
Ann Clarke¹, John Hanly², Yvan St.Pierre³, Caroline Gordon⁴, Sang-Cheol Bae⁵, Juanita Romero-Diaz⁶, Jorge Sanchez-Guerrero⁷, Sasha Bernatsky⁸, Daniel Wallace⁹, David Isenberg¹⁰, Anisur Rahman¹¹, Joan Merrill¹², Paul R Fortin¹³, Dafna Gladman¹⁴, Murray Urowitz¹⁵, Ian N. Bruce¹⁶, Michelle Petri¹⁷, Ellen Ginzler¹⁸, Mary Anne Dooley¹⁹, Rosalind Ramsey-Goldman²⁰, Susan Manzi²¹, Andreas Jnsen²², Graciela Alarcn²³, Ronald van Vollenhoven²⁴, Cynthia Aranow²⁵, Meggan Mackay²⁵, Guillermo Ruiz-Irastorza²⁶, S Sam Lim²⁷, Murat Inanc²⁸, Kenneth Kalunian²⁹, Soren Jacobsen³⁰, Christine Peschken³¹, Diane Kamen³², Anca Askanase³³ and Vernon Farewell³⁴, ¹University of Calgary, Calgary, AB, Canada, ²Dalhousie University, Halifax, NS, Canada, ³Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ⁴Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ⁵Hanyang University Medical Center, Seoul, Republic of Korea, ⁶Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Ciudad de México, Federal District, Mexico, ⁷Instituto Nacional de Ciencias Médicas y Nutrición, Inmunología y Reumatología, Mexico City, Mexico, ⁸McGill University, Montréal, QC, Canada, ⁹Cedars-Sinai, Los Angeles, CA, ¹⁰Centre for Rheumatology, University College London, London, United Kingdom, ¹¹University College London, London, United Kingdom, ¹²Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹³CHU de Quebec - Universite Laval, Québec City, QC, Canada, ¹⁴Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ¹⁵Center for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, University of Toronto, Lupus Clinic, Toronto, ON, Canada, ¹⁶University of Manchester, Manchester, United Kingdom, ¹⁷Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁸SUNY Downstate Health Sciences University, Brooklyn, NY, ¹⁹Raleigh Neurology Associates, Chapel Hill, NC, ²⁰Northwestern University, Chicago, IL, ²¹Allegheny Health Network, Wexford, PA, ²²Lund University, Lund, Sweden, ²³University of Alabama at Birmingham, Birmingham, AL, ²⁴Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Center, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ²⁵Feinstein Institutes for Medical Research, Manhasset, NY, ²⁶Hospital Universitario Cruces, University of the Basque Country, Bizkaia, Spain, ²⁷Department of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, GA, ²⁸Istanbul University Faculty of Medicine, Istanbul, Turkey, ²⁹UC San Diego, La Jolla, CA, ³⁰Rigshospitalet, Copenhagen, Denmark, ³¹University of Manitoba, Winnipeg, MB, Canada, ³²Medical University of South Carolina, Charleston, SC, ³³Columbia University Medical Center, New York, NY, ³⁴University of Cambridge, Cambridge, United Kingdom
Background/Purpose: Little is known about the economic burden of NP lupus. We estimated annual and cumulative direct and indirect costs (DC, IC) associated with NP…
Abstract Number: 0882 • ACR Convergence 2021
COVID-19 Impact Among Patients with Systemic Lupus Erythematosus
Jose Rubio¹, Suzanne krishfield¹ and Vasileios Kyttaris², ¹Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA, ²BIDMC, Boston, MA
Background/Purpose: Initial studies of SLE patients with COVID-19 revealed an increased risk for severe disease in people with distinct demographic features such as advanced age…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].